10x Genomics (TXG) Receivables - Other (2024 - 2026)

10x Genomics has disclosed Receivables - Other across 3 years of filings, most recently posting $3.1 million for Q2 2026.

• In Q2 2026, Receivables - Other fell 95.54% year-over-year to $3.1 million; the TTM figure through Jun 2026 stood at $3.1 million (down 95.54% YoY), while the FY2025 annual figure was $35.5 million, up 5754.79% from the prior year.
• Receivables - Other came in at $3.1 million for Q2 2026 at 10x Genomics, up from -$18.1 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $69.1 million in Q2 2025 to a low of -$18.1 million in Q1 2026.
• Average Receivables - Other over 3 years is $23.7 million, with a median of $19.3 million recorded in 2025.
• Year-over-year, Receivables - Other jumped 51877.45% in 2025 and plunged 95.54% in 2026.
• Over 3 years, Receivables - Other stood at -$102000.0 in 2024, then surged by 34884.31% to $35.5 million in 2025, then plunged by 91.31% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $3.1 million in Q2 2026, -$18.1 million in Q1 2026, and $35.5 million in Q4 2025.